BMY

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.18
Percentage change 0.31	%

Peers: PFE JNJ MRK LLY ABBV GILD AMGN AZN NVS

| Held by: VTI VOO SCHD SPY IVV VTV XLV COWZ VYM JEPI

Scroll to Statements

Index	S&P 500	P/E	-	EPS (ttm)	-3.60	Insider Own	0.08%	Shs Outstand	2.03B	Perf Week	0.19%
Market Cap	117.15B	Forward P/E	8.16	EPS next Y	7.08	Insider Trans	0.07%	Shs Float	2.03B	Perf Month	-1.89%
Income	-7258.00M	PEG	-	EPS next Q	1.47	Inst Own	77.73%	Short Float	1.36%	Perf Quarter	15.64%
Sales	47.44B	P/S	2.47	EPS this Y	-87.94%	Inst Trans	0.45%	Short Ratio	2.40	Perf Half Y	35.91%
Book/sh	8.45	P/B	6.83	EPS next Y	682.07%	ROA	-7.85%	Short Interest	27.66M	Perf Year	10.46%
Cash/sh	3.99	P/C	14.47	EPS next 5Y	-5.00%	ROE	-31.46%	52W Range	39.35 - 61.08	Perf YTD	12.57%
Dividend Est.	2.39 (4.14%)	P/FCF	8.49	EPS past 5Y	5.14%	ROI	-10.78%	52W High	-5.44%	Beta	0.44
Dividend TTM	2.40 (4.16%)	Quick Ratio	1.09	Sales past 5Y	16.92%	Gross Margin	55.87%	52W Low	46.79%	ATR (14)	1.30
Dividend Ex-Date	Jan 03, 2025	Current Ratio	1.24	EPS Y/Y TTM	-190.62%	Oper. Margin	17.62%	RSI (14)	53.14	Volatility	2.03% 2.08%
Employees	34100	Debt/Eq	3.00	Sales Y/Y TTM	5.56%	Profit Margin	-15.30%	Recom	2.57	Target Price	60.26
Option/Short	Yes / Yes	LT Debt/Eq	2.93	EPS Q/Q	-36.16%	Payout	59.82%	Rel Volume	0.31	Prev Close	57.58
Sales Surprise	5.57%	EPS Surprise	20.47%	Sales Q/Q	8.44%	Earnings	Oct 31 BMO	Avg Volume	11.50M	Price	57.76
SMA20	-0.18%	SMA50	2.53%	SMA200	17.26%	Trades		Volume	3,668,166	Change	0.31%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-24	Upgrade	Jefferies	Hold → Buy	$70
Dec-10-24	Resumed	BofA Securities	Neutral	$63
Nov-15-24	Initiated	Wolfe Research	Peer Perform
Nov-13-24	Upgrade	Daiwa Securities	Neutral → Outperform
Nov-12-24	Upgrade	Leerink Partners	Market Perform → Outperform	$73
Oct-25-24	Downgrade	Citigroup	Buy → Neutral	$75 → $55
Oct-17-24	Initiated	Bernstein	Mkt Perform	$56
Jul-29-24	Downgrade	Barclays	Overweight → Equal Weight	$41
Mar-11-24	Downgrade	Societe Generale	Buy → Hold
Feb-06-24	Downgrade	Redburn Atlantic	Buy → Neutral	$77 → $54
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $60
Nov-15-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$68 → $55
Nov-09-23	Initiated	Deutsche Bank	Hold	$55
Nov-02-23	Downgrade	Daiwa Securities	Outperform → Neutral	$68 → $54
Oct-27-23	Upgrade	HSBC Securities	Reduce → Hold	$55 → $53
Oct-27-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-27-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$60
Oct-20-23	Resumed	UBS	Neutral	$70 → $60
Jul-14-23	Initiated	HSBC Securities	Reduce	$56
Jul-10-23	Initiated	SVB Securities	Market Perform	$66

Show Previous Ratings

Dec-23-24 06:59AM	Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis (Business Wire)
06:45AM	Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite InstabilityHigh or Mismatch Repair Deficient Metastatic Colorectal Cancer (Business Wire)
Dec-19-24 02:28PM	Bristol Myers Squibb Stock Earns 83 RS Rating (Investor's Business Daily)
06:59AM	Bristol Myers Squibb to Report Results for Fourth Quarter 2024 on February 6, 2025 (Business Wire)
01:48AM	BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program (PR Newswire)
09:00AM	Loading…
Dec-18-24 09:00AM	insitro Receives $25 Million in Milestone Payments from Bristol Myers Squibb for the Achievement of Discovery Milestones and the Selection of First Novel Genetic Target for ALS (Business Wire)
08:45AM	Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic and Anal Cancers (GlobeNewswire)
Dec-17-24 06:30AM	Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline (TipRanks)
Dec-11-24 04:17PM	Bristol Myers Squibb Announces Dividend Increase (Business Wire)
Dec-09-24 05:45PM	Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline (Business Wire)
Dec-07-24 05:30AM	Dividend Stocks Are Primed for a Comeback in 2025 (The Wall Street Journal)
Dec-03-24 08:00AM	AI Proteins Announces Research Collaboration and Option Agreement with Bristol Myers Squibb for Miniprotein-Based Therapeutics Valued up to $400M (Business Wire)
Dec-02-24 07:44AM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
Nov-26-24 06:59AM	Bristol Myers Squibb to Participate in Citis 2024 Global Healthcare Conference (Business Wire)
Nov-22-24 04:09PM	AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback (Investor's Business Daily)
11:30AM	Loading…
11:30AM	AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback (Investor's Business Daily)
Nov-19-24 06:59AM	Bristol Myers Squibbs Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms (Business Wire)
Nov-18-24 07:30AM	Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer (Newsfile)
12:41AM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
Nov-15-24 07:22PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
08:23AM	Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite InstabilityHigh or Mismatch Repair Deficient Metastatic Colorectal Cancer (Business Wire)
06:59AM	Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors (Business Wire)
Nov-13-24 04:07PM	Avidity Bio Has Surged 416% This Year And That's Before Today's 'Game-Changing' News (Investor's Business Daily)
Nov-12-24 04:05PM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 3Q 2024 Results (GlobeNewswire)
07:00AM	What the NFL Draft Can Teach Investors About Big Pharma (The Wall Street Journal)
Nov-11-24 07:00PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research) +10.49%
04:32PM	S&P 500 Gains and Losses Today: Index Closes Above 6,000 on Post-Election Rally (Investopedia)
04:04PM	Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake' (Investor's Business Daily)
03:45PM	AbbVie tumbles on drug test disappointment, Bristol-Myers gains (Yahoo Finance Video)
10:12AM	Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails (Investor's Business Daily)
09:39AM	Loading…
09:39AM	AbbVie Stock Slides on Schizophrenia Drug Study Failure (The Wall Street Journal)
06:59AM	Bristol Myers Squibb Showcases the Continued Strength of its Cardiovascular Portfolio with New Clinical and Real-World Data at American Heart Association Scientific Sessions 2024 (Business Wire)
Nov-08-24 09:34AM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
Nov-05-24 05:00PM	Bristol Myers Squibb to Participate in Upcoming Investor Conferences (Business Wire)
Nov-01-24 03:07PM	Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade (Investor's Business Daily)
Oct-31-24 04:16PM	Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024 (Business Wire) +5.91%
04:12PM	Bristol Myers Screams To A Year-High After Walloping Profit Expectations (Investor's Business Daily)
02:43PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
10:03AM	Bristol Myers Squibb stock rises, Merck moves lower. Here's why. (Yahoo Finance Video)
07:12AM	Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance (Investor's Business Daily)
06:59AM	Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 (Business Wire)
Oct-29-24 11:17AM	Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure (Yahoo Finance)
Oct-28-24 06:59AM	Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 (Business Wire)
Oct-26-24 07:00AM	Pfizers Activist Battle Might Fizzlebut Its Stock Probably Wont (The Wall Street Journal)
Oct-16-24 04:21PM	Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction. (Investor's Business Daily)
Oct-15-24 06:09PM	Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment (Investor's Business Daily)
Oct-14-24 09:59PM	Jim Cramer on Bristol-Myers Squibb Company (BMY): 'I Think It's A Great Time To Consider Buying This One' (Insider Monkey)
Oct-07-24 05:30AM	Old Drug Repurposed for Schizophrenia Could Reap Alzheimers Windfall (The Wall Street Journal)
Oct-03-24 05:35PM	U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC) (Business Wire)
01:11PM	Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear (Investor's Business Daily)
Sep-30-24 07:00AM	Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies (GlobeNewswire)
Sep-27-24 07:38PM	U.S. Food and Drug Administration Approves Bristol Myers Squibbs COBENFY (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults (Business Wire)
04:18PM	Dow Rises to Record; Chinese Indexes Post Best Week in Years (The Wall Street Journal)
02:17PM	Dow Rises While Chinese Indexes Post Best Week in Years (The Wall Street Journal)
11:58AM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
11:06AM	Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting (Business Wire)
11:00AM	FDA approves new Bristol Myers Squibb schizophrenia drug (Yahoo Finance Video)
09:44AM	Dow, S&P 500 Rise at Open; Chinese Indexes Post Best Week in Years (The Wall Street Journal)
09:36AM	Bristol-Myers Stock Gains on FDA Approval for New Schizophrenia Drug (The Wall Street Journal)
06:59AM	U.S. Futures Point to a Muted Open as Investors Await Inflation Gauge (The Wall Street Journal)
05:59AM	Investors Await Feds Favored Inflation Gauge (The Wall Street Journal)
Sep-26-24 09:05PM	U.S. Food and Drug Administration Approves Bristol Myers Squibbs COBENFY (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults (Business Wire)
07:20PM	First Novel Schizophrenia Treatment in Decades Gains FDA Approval (The Wall Street Journal)
Sep-25-24 08:29PM	Bristol-Myers Squibb Company (BMY): Among the Dividend Giants with Lowest Short Interest in 2024 (Insider Monkey)
Sep-18-24 06:59AM	New Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple Sclerosis (Business Wire)
Sep-16-24 05:25AM	Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update (GlobeNewswire)
Sep-15-24 08:55AM	Bristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo plus Yervoy in Advanced Melanoma (Business Wire)
Sep-12-24 06:59AM	Bristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024 (Business Wire)
Sep-10-24 05:45PM	Bristol Myers Squibb Announces Dividend (Business Wire)
Sep-09-24 06:59AM	Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms (Business Wire)
Sep-08-24 02:30AM	Jim Cramer Says Eli Lilly and Company (LLY) Has the Biggest Pharmaceutical Potential (Insider Monkey)
Sep-06-24 07:00AM	Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research (Business Wire)
Sep-01-24 03:33AM	Long-Term Follow-Up Data from Phase 3 Study of CAMZYOS (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) (Business Wire)
Aug-28-24 06:19PM	Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday (Investopedia)
Aug-27-24 06:59AM	Bristol Myers Squibb to Participate in Upcoming Investor Conferences (Business Wire)
Aug-26-24 06:59AM	Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024 (Business Wire)
Aug-21-24 06:59AM	Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma (Business Wire)
Aug-19-24 06:59AM	European Medicines Agency Validates Bristol Myers Squibbs Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma (Business Wire)
Aug-16-24 07:30AM	The Feds Are Playing Nice With Pharma, At Least for Now (The Wall Street Journal)
Aug-15-24 05:30PM	These 10 drugs will be cheaper after Medicare negotiations (Yahoo Finance Video)
03:48PM	Medicare Enrollees Will See Significant Price Reductions For 10 Drugs (Investopedia)
12:34PM	Medicare negotiates lower prices for 10 high-cost drugs (Yahoo Finance Video)
10:49AM	Big Pharma: The government revealed its list of negotiated drug prices. Here are the reactions. (Yahoo Finance)
07:49AM	Medicare to save $6B in 2026 from the first ever Part D drug pricing negotiations (Yahoo Finance)
Aug-08-24 06:30AM	Big Pharma Cuts R&D, Sending Shudders Through Industry (The Wall Street Journal)
Jul-29-24 06:30AM	Big Pharma Rallies and Moves Past Obesity (The Wall Street Journal)
Jul-27-24 11:31AM	Why Wall Street is unfazed by Medicare drug pricing threat (Yahoo Finance)
Jul-26-24 07:06PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research) +11.44%
01:26PM	Stocks jump on cool inflation data, 3M pops on earnings: Yahoo Finance (Yahoo Finance Video)
11:33AM	Stocks to Watch Friday: DexCom, 3M, Coinbase, Charter (The Wall Street Journal)
10:36AM	Bristol-Myers Squibb Beats Q2 Expectations, Boosts Guidance on Rising Drug Sales (Investopedia)
08:55AM	Stock Futures Rise as Chip Shares Rally (The Wall Street Journal)
06:59AM	Bristol Myers Squibb Reports Second Quarter Financial Results for 2024 (Business Wire)
04:57AM	Pressure on Stocks Eases at End of Turbulent Week (The Wall Street Journal)
Jul-25-24 06:03PM	June PCE, Bristol Myers Squibb earnings: What to watch Friday (Yahoo Finance Video)
Jul-19-24 06:59AM	Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma (Business Wire)
Jul-11-24 02:23PM	3 Under-$10 Biotech Stocks That Could Make You Rich (InvestorPlace)
Jul-10-24 12:00PM	3 Undervalued Stocks Ready for a Breakout This Summer (InvestorPlace)
Jul-09-24 07:40AM	The 7 Best Warren Buffett Stocks to Buy in July 2024 (InvestorPlace)
Jul-08-24 06:59AM	Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day (Business Wire)

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Holzer Phil M	SVP and Controller	Nov 04 '24	Sale	55.62	700	38,930	11,760	Nov 05 05:53 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Nov 01 '24	Option Exercise	0.00	2,964	0	104,169	Nov 05 05:42 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Nov 01 '24	Buy	54.67	1,830	100,055	62,109	Nov 05 05:41 PM
Holzer Phil M	Officer	Nov 04 '24	Proposed Sale	55.62	700	38,930		Nov 04 11:20 AM
Gallman Cari	EVP, Corporate Affairs	Oct 02 '24	Option Exercise	0.00	4,558	0	6,667	Oct 03 06:33 PM
Gallman Cari	EVP, Corporate Affairs	Aug 01 '24	Option Exercise	0.00	1,061	0	2,493	Aug 05 06:01 PM
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Apr 01 '24	Option Exercise	0.00	3,306	0	6,532	Apr 02 06:45 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	Mar 10 '24	Option Exercise	0.00	15,016	0	13,859	Mar 12 09:54 PM
LEUNG SANDRA	EVP, General Counsel	Mar 10 '24	Option Exercise	0.00	46,784	0	371,312	Mar 12 09:43 PM
Plenge Robert M	EVP, Chief Research Officer	Mar 10 '24	Option Exercise	0.00	9,143	0	15,182	Mar 12 09:21 PM
Poole Ahn Amanda	EVP, Chief Human Resources	Mar 10 '24	Option Exercise	0.00	5,458	0	4,841	Mar 12 09:11 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Mar 10 '24	Option Exercise	0.00	38,388	0	80,256	Mar 12 08:40 PM
Holzer Phil M	SVP and Controller	Mar 10 '24	Option Exercise	0.00	5,520	0	14,916	Mar 12 08:31 PM
Hoch Lynelle	President, Cell Therapy Org.	Mar 10 '24	Option Exercise	0.00	4,351	0	3,781	Mar 12 08:01 PM
Gallman Cari	EVP, Corporate Affairs	Mar 10 '24	Option Exercise	0.00	2,761	0	2,655	Mar 12 08:00 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Mar 10 '24	Option Exercise	0.00	54,638	0	129,769	Mar 12 07:58 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10 '24	Option Exercise	0.00	64,326	0	225,111	Mar 12 05:43 PM
Caforio Giovanni	Executive Chair of the Board	Mar 10 '24	Option Exercise	0.00	190,130	0	529,662	Mar 12 05:42 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Feb 01 '24	Option Exercise	0.00	2,543	0	6,040	Feb 05 07:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Bristol-Myers Squibb Co

Upgrade your FINVIZ experience